Background/Objectives: Breast cancer (BC) is the most commonly diagnosed cancer worldwide. Estrogen receptor (ER) status is a key determinant in the diagnosis and treatment of BC. Although immunohistochemistry (IHC) is the gold standard for ER assessment, it has limitations. This umbrella review aims to evaluate the role of 16α-18F-fluoro-17β-estradiol ([18F]FES) PET/CT as a non-invasive imaging tool for assessing ER expression and its implications in BC management. Methods: A comprehensive search was conducted in PubMed/MEDLINE and Cochrane Library for systematic reviews and meta-analyses published in the last decade. Studies eligible for inclusion evaluated the diagnostic accuracy and clinical utility of [18F]FES PET/CT in BC based on a predefined research question “What is the role of fluoroestradiol ([18F]FES) PET/CT in breast cancer?”. Data extraction and quality assessment were performed independently by two reviewers using the AMSTAR-2 tool. Results: Eight systematic reviews met the inclusion criteria. [18F]FES PET/CT demonstrated high sensitivity (81–94%) and specificity (78–95%) in detecting ER-positive lesions. It provided a real-time, whole-body assessment of ER expression, outperforming IHC in detecting functional ER activity. Additionally, [18F]FES PET/CT showed promise in predicting treatment response and guiding therapy decisions, particularly in metastatic settings. Conclusions: This review highlights the clinical value of [18F]FES PET/CT in BC management, offering a non-invasive alternative for ER assessment with high diagnostic accuracy. Its integration into clinical practice may enhance personalized treatment strategies for BC patients.
Purpose: Neurological paraneoplastic syndromes (PNS) occur in less than 1% of patients with cancer but carry a significant clinical burden. Prognosis strongly depends on timely diagnosis and treatment. This study presents an illustrative case series and a structured review of neurological PNS in a gynecological context. This case series describes four patients (ages 61–79) with neurological PNS with underlying breast or pelvic malignancies, diagnosed with anti-amphiphysin encephalitis, autoimmune myeloradiculitis, and paraneoplastic cerebellar ataxia. Methods: A structured literature review focusing on neurological PNS in gynecological and breast oncology with at least two participants was conducted using PubMed and MEDLINE. The results are synthesized, focusing on diagnostic workup and clinical findings. Results: The review identified 5 original studies comprising 72 patients. Most cases were associated with breast cancer; however, largely attributable to one large study. Neurological PNS should be considered once alternative etiologies have been excluded through appropriate diagnostic testing. Most often this includes neurologic imaging. Diagnosis requires antibody testing and subsequent malignancy investigation, guided by the specific antibody profiles. Main limitations were the influence of one large study with the remaining sample sizes being small, as well as the retrospective study designs. Conclusion: Due to their rarity and complexity, neurological PNS pose significant diagnostic and treatment challenges. Since neurological symptoms often precede the cancer diagnosis, thorough diagnostics and prompt treatment are essential, as prognosis is time-sensitive. Multidisciplinary care is crucial, and further research is necessary to improve understanding and management of these syndromes.